Q BioMed Inc.

Q BioMed Announces FDA Approval

LogoQ BioMed Inc. (QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC. ITG is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP.

Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development

LogoQ BioMed Inc., a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc.

Q BioMed Adds Big Pharma Executive to Board of Directors

LogoQ BioMed Inc., a biotechnology acceleration company, is pleased to welcome Dr. Rick Panicucci as an independent member on its board of Directors.

Q BioMed Adds Boston University's Dr. Helen Tager-Flusberg to Advisory Committee

LogoQ BioMed Inc., a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.

Q BioMed Inc. Announces Development Partnership with Sphaera Pharma

LogoQ BioMed Inc., a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.

Q Biomed Inc. Adds Nuclear Medicine Industry Veteran to Commercialization Team

LogoQ BioMed Inc, a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.

Q Biomed Inc Announces Two New Members to Its Scientific Advisory Board

LogoQ BioMed Inc., a biotechnology acceleration company is pleased to announce the appointment of Dr. Amy Ripka and Dr. Rick Panicucci to its board of scientific advisors.

Q Biomed Inc. Completes Final Closing on $4,000,000 Funding

LogoQ BioMed Inc., has closed on its final tranche of the $4,000,000 funding announced on November 30th, 2016. The company received $1,500,000 less fees on the final closing bringing the total gross funds received to date to $4MM.

Q Biomed Joins with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology to Develop Liver Cancer Chemotherapeutic

LogoQ BioMed, Inc. has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.

Q BioMed Provides Update on Corporate Developments

LogoQ BioMed Inc., a biotechnology acceleration company is pleased to report on its asset acquisition and an update on corporate development.

Visit Our Other Sites:

Submit News